Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abarelix vs Goserelin + Bicalutamide in Advanced Prostate Cancer
NCT00841113Phase 3Completed
- Sponsor
- Speciality European Pharma
- Start
- Jan 1999
- Primary completion
- Feb 2001
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of abarelix in prostate cancer (PCa) (2 arms), sponsored by Speciality European Pharma. Primary endpoint: Comparative castration rates one week after starting therapy at 1 week. Started Jan 1999; status: completed.
02
Drugs
abarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00841113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841113.